5 results match your criteria: "University Hospital Spedali Civili of Brescia[Affiliation]"
Fate of melatonin orally administered in preterm newborns: Antioxidant performance and basis for neuroprotection.
J Pineal Res
January 2024
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Article Synopsis
- * A study was conducted to investigate the production of melatonin (ME) in very preterm infants, the metabolism of ME after oral treatment, and the impact on MDA concentrations over 15 days.
- * Results showed that while preterm infants couldn't produce measurable levels of ME initially, those who received ME treatment had significant increases in ME and its metabolite 6-OH-ME, but MDA levels remained relatively stable with a slight trend towards improvement in the ME group.
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis.
Ophthalmol Ther
April 2022
Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Article Synopsis
- - The article discusses the creation and implementation of a global registry by the AIDA Network to gather data from both pediatric and adult patients with immune-mediated scleritis.
- - Using the REDCap tool, the registry collects a wide range of data securely, while allowing for adaptability as scientific knowledge grows and enabling collaboration with other registries for sustainability.
- - Since its inception, the registry has engaged 99 centers across 20 countries, collecting comprehensive data to enhance research and improve clinical management of this rare ocular inflammatory condition.
Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study.
Front Pediatr
May 2019
Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. Propranolol 0.1% eye micro-drops administered to newborns with stage 2 ROP are well-tolerated, but not sufficiently effective.
View Article and Find Full Text PDFStudy protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.
BMC Pediatr
July 2017
Neonatal Intensive Care Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
Background: Retinopathy of prematurity (ROP) still represents one of the leading causes of visual impairment in childhood. Systemic propranolol has proven to be effective in reducing ROP progression in preterm newborns, although safety was not sufficiently guaranteed. On the contrary, topical treatment with propranolol eye micro-drops at a concentration of 0.
View Article and Find Full Text PDFMitochondrial diseases: a nosological update.
Acta Neurol Scand
April 2007
Neurological Clinic, Section for Neuromuscular Diseases and Neuropathies, University Hospital Spedali Civili of Brescia, Brescia, Italy.
Mitochondrial diseases are disorders caused by impairment of the mitochondrial respiratory chain, characterized by clinical-genetic heterogeneity and frequent multisystemic involvement. It is difficult to establish a precise genotype/phenotype correlation and obtain a definitive nosology. Today's genetic classification distinguishes disorders caused by defects in the mitochondrial genome (sporadic or maternally-inherited) from disorders caused by defects in the nuclear genome (autosomally-inherited).
View Article and Find Full Text PDF